Cencora — Nov 5, 2025 release

Healthcare Solutions Segment (1) 9% to 11% growth $3.3B International Healthcare Solutions Segment (1)(2) 5% to 8% growth $588M Other (1) 1% to 4% decline $352M Adjusted diluted earnings per share $17.45 to $17.75 $16.00 Net interest expense $315M to $335M $292M Adjusted effective tax rate 20% to 21% 20.6% Diluted weighted average shares outstanding ~194M 195.2M Adjusted free cash flow ~$3.0B $3.0B Capital expenditures ~$900M $668M (1) For further detail on fiscal 2025 revised reportable segment information, please reference Exhibit 99.2 to the Company's form 8-K dated November 5, 2025. (2) As reported and constant currency guidance. Long-Term Guidance To reflect the strength in the Company's businesses and continued execution, the Company is raising its long-term guidance for adjusted diluted EPS and adjusted operating income. Long-term guidance (1) Adjusted operating income 6% to 9% Capital deployment 3% to 4% Adjusted diluted earnings per share 9% to 13% (1) Bold numbers indicate updates to guidance ranges. Conference Call & Slide Presentation The Company will host a conference call to discuss the results at 8:30 a.m. ET on November 5, 2025. A slide presentation for investors has also been posted on the Company’s website at investor.cencora.com. The dial-in number for the live call will be (833) 470-1428. From outside the United States and Canada, dial +1 (646) 844-6383. The access code for the call will be 837725. The live call will also be webcast via the Company’s website at investor.cencora.com. Users are encouraged to log on to the webcast approximately 10 minu